ResMed Inc
(BSP:R1MD34)
R$
381
9.84 (2.65%)
Market Cap: 223.72 Bil
Enterprise Value: 226.25 Bil
PE Ratio: 32.98
PB Ratio: 7.04
GF Score: 86/100 Resmed Inc at KeyBanc Capital Markets Life Sciences & Medtech Investor Forum (virtual) Transcript
Mar 23, 2021 / 08:15PM GMT
Release Date Price:
R$259.21
Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst
All right. Good afternoon, and welcome to the last fireside chat of the day for the inaugural KeyBanc Life Sciences and Med Tech Investor Forum. My name is Matt Mishan. I'm a senior med tech analyst. I'm pleased to be joined by CFO, Brett Sandercock; and COO, Rob Douglas from ResMed. If you have any questions, there is a Q&A on the -- a Q&A box in the bottom of the screen that goes to me, and I'll do my best to get to them.
Questions & Answers
Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst
So to start it off, Brett, Rob, how would you characterize the transition from December-January surge to kind of February-March vaccine optimism that we're starting to see?
Robert A. Douglas
ResMed Inc. - President & COO
Yes, Matt, I think in terms of the longer-term picture over the last year and through to where we are, we continue to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot